☰
Skip to content
Home
Studies
BioFINDER One
BioFINDER Two
BioFINDER Sleep
BioFINDER Preclinical AD
BioFINDER Primary Care
BioFINDER Memory Clinic
Study Group
Publications
News
Deltagare / Participants
Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders.
2024
Brain Commun. 2024 Nov 19;6(6):fcae414. doi: 10.1093/braincomms/fcae414. eCollection 2024.PMID: 39605973 Free PMC article.
Fernandes Gomes B, Kumar A, Ashton NJ, Hall S, Stomrud E, Smith R, Zetterberg H, Blennow K, Mattsson-Carlgren N,
Hansson O.
Brain Commun. 2024 Nov 19;6(6):fcae414. doi: 10.1093/braincomms/fcae414. eCollection 2024.PMID: 39605973
Free PMC article.
2026
A minimally invasive dried blood spot biomarker test for the detection of Alzheimer’s disease pathology
2026
Associations of modifiable and non-modifiable risk factors with longitudinal white matter hyperintensities, amyloid-β and tau – a prospective cohort study
2026
A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease
2025
STEM-PD trial protocol: a multi-centre, single-arm, first-in-human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease
2025
Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group
2025
Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies
2025
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid
2025
Locus coeruleus-entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein
2025
Assessment of myocardial sympathetic innervation with [123I]mIBG myocardial scintigraphy: A comparative study between an Anger and a ring-configured cadmium-zinc-telluride gamma camera.
2025
Characterizing the onset and progression of Alzheimer’s pathologies using amyloid and tau PET imaging and plasma p-tau217
2025
Taurine Intake, Plasma Taurine Concentration, and Dementia Risk: Findings From the Malmö Diet and Cancer Study
2025
CSF pTDP-43 across the Alzheimer’s spectrum: Links to amyloid, APOE and vasculopathy
2025
The tau biomarker cascade is condensed in Down syndrome compared to sporadic Alzheimer’s disease
2025
Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
2025
Estimating the time course of biomarker changes in Alzheimer’s disease